Novo Nordisk Adds Momentum To Oral Semaglutide With Good PIONEER 5 Data
Novo Nordisk announced another set of positive PIONEER trial data backing its oral GLP-1 receptor agonist semaglutide, this time showing superior reduction of blood sugar levels and weight in adults with type 2 diabetes compared with placebo.
You may also be interested in...
Pricing pressure and difficulties with market access in competitive classes will be common themes as Teva, Novo Nordisk and Shire report third quarter sales and earnings.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.